CytoSorbents, Progenity Receive Funding For Product Development

The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation CTSO, a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract of $1.5 million over 28 months.

  • The funding will be used to advance the development of the K+ontrol platform to treat severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine.
  • Price Action: CTSO shares are up 0.63% at $7.96 during the market trading session on the last check Tuesday.

Progenity Inc PROG has received funding from the Crohn's & Colitis Foundation's IBD Ventures program to further develop its oral Drug Delivery System to deliver targeted therapeutics for inflammatory bowel disease.

  • Progenity's lead candidates include PGN-001, a high-concentration formulation of adalimumab, and PGN-600, a high concentration, solubilized formulation of tofacitinib.
  • Price Action: PROG shares are trading 5.7% higher at $2.49 during the market trading session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechGovernmentNewsPenny StocksHealth CareFinancingSmall CapFDAGeneralBriefsUS Army
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!